Navigation Links
HPV virus helps cervical and head and neck cancers resist treatment and grow and spread
Date:11/3/2008

The human papillomavirus (HPV) allows infected cervical and head and neck cancer cells to maintain internal molecular conditions that make the cancers resistant to therapy and more likely to grow and spread, resulting in a poor prognosis for patients, researchers with UCLA's Jonsson Cancer Center found.

Virtually all human cancers experience a state called intratumoral hypoxia, or a low amount of oxygen within the tumor. In the UCLA study, researchers showed that the HPV-positive cancers adapted to and took advantage of the hypoxic environment by expressing a protein that activates a cell signaling pathway that helps the cancers survive, grow and spread.

The study is published in the Nov. 4, 2008 issue of the journal Cancer Cell.

The research, done on cells in culture and in animal models, may lead to the development of new therapies that target the cell signaling pathway, thereby interrupting ability of the cancer cells to thrive, said Dr. Matthew Rettig, senior author of the study and a researcher at UCLA's Jonsson Comprehensive Cancer Center.

"There is potential for therapeutic intervention based on this finding," said Rettig, an associate professor of urology and medicine.

The finding is crucial because 90 to 98 percent of cervical cancers are caused by HPV. Cervical cancer is the second most common cancer in women worldwide, with more than 500,000 cases diagnosed annually. In all, 200,000 women die from cervical cancer every year. In oral cavity and pharynx cancers, the HPV virus is linked to about 20 to 40 percent of cases, caused by sexual behavior. About 400,000 cases of head and neck cancer are diagnosed worldwide each year, and more than half of those patients die of the disease.

In those cases where the cancer is HPV-positive, which number in the hundreds of thousands, the virus will make the disease more aggressive and deadly. Finding a way to stop the virus from prompting the cance
'/>"/>

Contact: Kim Irwin
kirwin@mednet.ucla.edu
310-206-2805
University of California - Los Angeles
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Smaller mosquitoes are more likey to be infected with viruses causing human diseases
2. Special Mouth Rinse Spots, Tracks Human Papillomavirus Infection
3. HIV Test Kit Markets a New Development in the War Against the AIDS Virus, an Easy Home HIV Testing Device
4. How to select anti-hepatitis B virus agents for drug-resistance patients?
5. Pitt research indicates new virus is culprit, not bystander, in deadly skin cancer
6. The prevalence of hepatitis B virus infection in inflammatory bowel disease patients
7. A potential approach to treatment of hepatitis B virus infection
8. Early treatment is key to combating hepatitis C virus
9. Researchers Find Genes That Influence West Nile Virus
10. HIV Drug Might Spur Resistant Strains of Virus
11. USPTO Issues Patent Embodying Methodologies for Abating a Broad Range of Allergens, Pathogens, Viruses, Bacteria, Odors and Volatile Organic Compounds.
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Patent Expiries of Blockbuster Antibiotics Will Fuel a Decline of More Than 15 Percent in the Community-Acquired Pneumonia Drug Market 2Pivotal Trial Data Demonstrate NeuroPace RNS(R) System Reduced Seizures in People With Epilepsy 2Pivotal Trial Data Demonstrate NeuroPace RNS(R) System Reduced Seizures in People With Epilepsy 3Pivotal Trial Data Demonstrate NeuroPace RNS(R) System Reduced Seizures in People With Epilepsy 4Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 2Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 3Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 4Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 5Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 6QLT Announces Second Quarter Results for 2009 52895 1QLT Announces Second Quarter Results for 2009 52895 2QLT Announces Second Quarter Results for 2009 52895 3QLT Announces Second Quarter Results for 2009 52895 4QLT Announces Second Quarter Results for 2009 52895 5QLT Announces Second Quarter Results for 2009 52895 6QLT Announces Second Quarter Results for 2009 52895 7QLT Announces Second Quarter Results for 2009 52895 8QLT Announces Second Quarter Results for 2009 52895 9QLT Announces Second Quarter Results for 2009 52895 10QLT Announces Second Quarter Results for 2009 52895 11QLT Announces Second Quarter Results for 2009 52895 12QLT Announces Second Quarter Results for 2009 52895 13QLT Announces Second Quarter Results for 2009 52895 14QLT Announces Second Quarter Results for 2009 52895 15QLT Announces Second Quarter Results for 2009 52895 16QLT Announces Second Quarter Results for 2009 52895 17NeoGenomics Reports Second Quarter 2009 Results 13224 1NeoGenomics Reports Second Quarter 2009 Results 13224 2NeoGenomics Reports Second Quarter 2009 Results 13224 3NeoGenomics Reports Second Quarter 2009 Results 13224 4NeoGenomics Reports Second Quarter 2009 Results 13224 5NeoGenomics Reports Second Quarter 2009 Results 13224 6NeoGenomics Reports Second Quarter 2009 Results 13224 7NeoGenomics Reports Second Quarter 2009 Results 13224 8NeoGenomics Reports Second Quarter 2009 Results 13224 9GeneGo Awarded NIH Grant to Develop Pharmacogenomics Software Suite 52890 1GeneGo Awarded NIH Grant to Develop Pharmacogenomics Software Suite 52890 2